In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. After subcutaneous injection insulin glargine is partly converted into the two main metabolites M1 ([Gly(A21)]insu...
Main Authors: | Mark R Sommerfeld, Günter Müller, Georg Tschank, Gerhard Seipke, Paul Habermann, Roland Kurrle, Norbert Tennagels |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2832019?pdf=render |
Similar Items
-
Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
by: Cécile Pierre-Eugene, et al.
Published: (2012-01-01) -
The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
by: Xiaoli Sheng, et al.
Published: (2019-08-01) -
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01) -
Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
by: Mamatha Garige, et al.
Published: (2023-03-01) -
Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)